title: Gender differences in the renal response to renin-angiotensin system blockade.
abstract: Evidence suggests that gender differences exist in renin-angiotensin system (RAS) function. It was hypothesized that women may differ also in their response to RAS blockade. The renal and peripheral hemodynamic responses to incremental dosages of an angiotensin receptor blocker and the degree of angiotensin II (AngII) insensitivity achieved during 8 wk were examined in men and women. Participants were 30 young healthy men (n = 15; mean age 27 +/- 2) and women (n = 15; mean age 28 +/- 2) who were on a controlled sodium and protein diet for 1 wk before each study. The humoral, renal, and systemic response to incremental dosages of irbesartan (75 mg for 4 wk, then 150 mg for 4 wk) was assessed, as was the pressor response to AngII (3 ng/kg per min), at 2-wk intervals. AngII type 1 receptor expression in skin biopsies was assessed at baseline and after 8 wk by a real-time PCR protocol. Men and women both exhibited significant declines in BP. Women achieved significantly reduced AngII sensitivity compared with men at lower dosages, showing no pressor response at 4 wk of 75 mg/d irbesartan, whereas men continued to exhibit a pressor response at 4 wk of 150 mg/d. Receptor expression at baseline did not differ between men and women but by 8 wk was significantly decreased in women and unchanged in men. Our findings indicate that men may require larger dosages of angiotensin receptor blocker than do women and that the BP response cannot be used as a surrogate marker for adequate RAS blockade of the renal microvasculature.
authors.affiliation: Toronto General Hospital, 8N-846, 585 University Avenue, Toronto, Ontario, M5G 2N2. judith.miller@utoronto.ca
authors.forename: Judith A
authors.initials: JA
authors.lastname: Miller
authors.forename: David Z
authors.initials: DZ
authors.lastname: Cherney
authors.forename: John A
authors.initials: JA
authors.lastname: Duncan
authors.forename: Vesta
authors.initials: V
authors.lastname: Lai
authors.forename: Kevin D
authors.initials: KD
authors.lastname: Burns
authors.forename: Christopher R J
authors.initials: CR
authors.lastname: Kennedy
authors.forename: Joseph
authors.initials: J
authors.lastname: Zimpelmann
authors.forename: Wei
authors.initials: W
authors.lastname: Gao
authors.forename: Daniel C
authors.initials: DC
authors.lastname: Cattran
authors.forename: James W
authors.initials: JW
authors.lastname: Scholey
mesh_terms: D000328:Adult; D047228:Angiotensin II Type 1 Receptor Blockers / Q000494:pharmacology*; D001713:Biphenyl Compounds / Q000494:pharmacology*; D001794:Blood Pressure / Q000187:drug effects; D005260:Female; D006801:Humans; D000077405:Irbesartan; D007668:Kidney / Q000098:blood supply; D008297:Male; D008833:Microcirculation / Q000187:drug effects; D012079:Renal Circulation / Q000187:drug effects; D012083:Renin / Q000097:blood; D012084:Renin-Angiotensin System / Q000187:drug effects*; D012737:Sex Factors; D013777:Tetrazoles / Q000494:pharmacology*
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D001713:Biphenyl Compounds; D013777:Tetrazoles; D012083:Renin; D000077405:Irbesartan